SERPING1 and hereditary angioedema: Treatment with lanadelumab Q2W reduced the rate of HAE attack per 28 days by 82.1% compared with C1-INH(IV) 1000 IU (RR: 0.1792 [95% CI: 0.0296–1.0853]), and by 88.9% compared with C1-INH(IV) 500 IU (RR: 0.1107 [95% CI: 0.0234–0.5239]) (Table 1 and Figure 1).